Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA)
28 juil. 2021 07h30 HE
|
Abeona Therapeutics Inc.
Transpher A; pivotal study for intended registration of ABO-102 for MPS IIIA disease Alignment with FDA on primary study endpoint NEW YORK and CLEVELAND, July 28, 2021 (GLOBE NEWSWIRE) -- Abeona...
Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy
26 juil. 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 26, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene therapy, today announced magnetic resonance imaging (MRI) data...
Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL™ Study for Recessive Dystrophic Epidermolysis Bullosa
23 juil. 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 23, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the activation of a second...
Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting
07 juil. 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced updated Phase 1/2a clinical...
Abeona Therapeutics to Present at Jefferies Virtual Healthcare Conference
02 juin 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, June 02, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, President...
Abeona Therapeutics Issues Letter to Stockholders
26 mai 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 26, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today issued the following letter to...
Abeona Therapeutics Appoints Head of Research & Clinical Development
25 mai 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 25, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Vishwas...
Abeona Therapeutics Reports First Quarter Financial Results
18 mai 2021 07h30 HE
|
Abeona Therapeutics Inc.
Patient enrollment ongoing for EB-101 pivotal Phase 3 VIITAL™ study Positive interim MPS III data presented at 17th Annual WORLDSymposium; additional neurocognitive assessments of patients treated in...
Abeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Stargardt Disease at ARVO 2021 Annual Meeting
20 avr. 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, April 20, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that new data from its...
Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors
19 avr. 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, April 19, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Dr. Leila...